Americana Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Americana Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-338	Closed	-$261K	–	629
2026 Q1	$261K	Buy	+338	New	+$259K	0.01%	447
2025 Q1	–	Sell	-350	Closed	-$249K	–	405
2024 Q4	$249K	Buy	350 +36	+11%	+$30.2K	0.01%	355
2024 Q3	$330K	Buy	+314	New	+$349K	0.02%	297
2020 Q1	–	Sell	-104	Closed	-$39K	–	400
2019 Q4	$39K	Buy	+104	New	+$35K	0.02%	255

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Americana Partners's REGN Position: Q2 2026 in Review

Americana Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 338 shares — an estimated $261K sold.

Americana Partners first reported a position in REGN in Q4 2019 and held it in 4 quarters. The position peaked at $330K in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Americana Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Americana Partners sold 338 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $261K.
Americana Partners first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Americana Partners's Regeneron Pharmaceuticals position peaked at $330K in Q3 2024.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Americana Partners's 13F filing for Q2 2026, filed 5 Aug 2026.